At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Lenalidomide and Low Dose Dexamethasone in Patients With High-Risk Smoldering Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Lenalidomide, and 1 other intervention for Smoldering Multiple Myeloma. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma. \- Patients with smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. Patients with active multiple myeloma generally require treatment.
Study Details
Timeline
Interventions
Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
Oral, predetermined dosage, Days 1-21 of cycle 1-12
Oral, Days 1, 8, 15 of cycle 1-6